Drug Profile
AUT 00206
Alternative Names: AUT-00206Latest Information Update: 20 Oct 2022
Price :
$50
*
At a glance
- Originator Autifony Therapeutics; University of Manchester; University of Newcastle upon Tyne
- Class Antipsychotics; Small molecules
- Mechanism of Action Shaw potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fragile X syndrome
- Discontinued Schizophrenia
Most Recent Events
- 20 Oct 2022 Discontinued - Phase-I for Schizophrenia in United Kingdom (PO)(Autifony Therapeutics pipeline, October 2022)
- 06 Oct 2022 AUT 00206 is still in phase-I trials for Fragile X syndrome in United Kingdom (PO)(Autifony Therapeutics pipeline, October 2022)
- 06 Oct 2022 Autifony Therapeutics plans a phase-II trial for Fragile-X-syndrome (Autifony Therapeutics pipeline, October 2022)